Cypress Capital Management (Wyoming)’s Tvardi Therapeutics TVRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-139
Closed -$1.54K 166
2024
Q3
$1.54K Hold
139
﹤0.01% 141
2024
Q2
$1.29K Hold
139
﹤0.01% 146
2024
Q1
$4.55K Sell
139
-10
-7% -$259 ﹤0.01% 125
2023
Q4
$3.98K Hold
149
﹤0.01% 125
2023
Q3
$8.99K Hold
149
0.01% 113
2023
Q2
$15.1K Hold
149
0.02% 90
2023
Q1
$26.3K Hold
149
0.03% 83
2022
Q4
$57.5K Sell
149
-58
-28% -$22K 0.07% 67
2022
Q3
$70K Sell
207
-239
-54% -$86.6K 0.1% 60
2022
Q2
$146K Hold
446
0.19% 45
2022
Q1
$195K Sell
446
-16
-3% -$6.57K 0.23% 45
2021
Q4
$203K Buy
+462
New +$232K 0.17% 71
2021
Q3
Sell
-465
Closed -$233K 326
2021
Q2
$239K Sell
465
-1,544
-77% -$978K 0.18% 75
2021
Q1
$1.57M Sell
2,009
-248
-11% -$170K 1.38% 27
2020
Q4
$1.23M Sell
2,257
-2,721
-55% -$1.43M 1.06% 32
2020
Q3
$2.51M Sell
4,978
-20
-0.4% -$11.6K 2.25% 12
2020
Q2
$3.08M Sell
4,998
-1
-0% -$552 3.07% 7
2020
Q1
$2.38M Sell
4,999
-114
-2% -$62K 3.35% 7
2019
Q4
$2.97M Buy
+5,113
New +$3.59M 2.8% 7
2018
Q3
Sell
-2,068
Closed -$1.49M 373
2018
Q2
$1.43M Buy
+2,068
New +$1.05M 1.5% 19

Other funds holding TVRD

Cypress Capital Management (Wyoming)'s TVRD Position: Q4 2024 in Review

Cypress Capital Management (Wyoming) sold out of Tvardi Therapeutics (TVRD) in Q4 2024, closing a stake of 139 shares — an estimated $1.54K sold.

Cypress Capital Management (Wyoming) first reported a position in TVRD in Q2 2018 and held it in 20 quarters. The position peaked at $3.08M in Q2 2020. 43 funds tracked by Wall St. Rank hold TVRD as of Q4 2024.

  • Cypress Capital Management (Wyoming) reported no remaining Tvardi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cypress Capital Management (Wyoming) sold 139 Tvardi Therapeutics shares in Q4 2024, an estimated $1.54K.
  • Cypress Capital Management (Wyoming) first reported a position in Tvardi Therapeutics in Q2 2018 and held it in 20 quarters.
  • Cypress Capital Management (Wyoming)'s Tvardi Therapeutics position peaked at $3.08M in Q2 2020.
  • 43 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2024.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q4 2024, filed 23 Jan 2025.